Free Trial
NASDAQ:CELC

Celcuity (CELC) Stock Price, News & Analysis

Celcuity logo
$14.55 -0.09 (-0.61%)
(As of 10:38 AM ET)

About Celcuity Stock (NASDAQ:CELC)

Key Stats

Today's Range
$14.47
$15.22
50-Day Range
$13.98
$16.35
52-Week Range
$11.79
$22.19
Volume
46,319 shs
Average Volume
274,930 shs
Market Capitalization
$538.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.17
Consensus Rating
Buy

Company Overview

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Celcuity Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
44th Percentile Overall Score

CELC MarketRank™: 

Celcuity scored higher than 44% of companies evaluated by MarketBeat, and ranked 706th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Celcuity has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Celcuity has only been the subject of 2 research reports in the past 90 days.

  • Read more about Celcuity's stock forecast and price target.
  • Earnings Growth

    Earnings for Celcuity are expected to decrease in the coming year, from ($2.54) to ($3.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Celcuity is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Celcuity is -5.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Celcuity has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Celcuity's valuation and earnings.
  • Percentage of Shares Shorted

    9.42% of the outstanding shares of Celcuity have been sold short.
  • Short Interest Ratio / Days to Cover

    Celcuity has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Celcuity has recently decreased by 1.13%, indicating that investor sentiment is improving.
  • Dividend Yield

    Celcuity does not currently pay a dividend.

  • Dividend Growth

    Celcuity does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.42% of the outstanding shares of Celcuity have been sold short.
  • Short Interest Ratio / Days to Cover

    Celcuity has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Celcuity has recently decreased by 1.13%, indicating that investor sentiment is improving.
  • News Sentiment

    Celcuity has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Celcuity this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,688.00 in company stock.

  • Percentage Held by Insiders

    15.78% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.33% of the stock of Celcuity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Celcuity's insider trading history.
Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

CELC Stock News Headlines

Celcuity (CELC) Gets a Buy from Craig-Hallum
With the “Bitcoin Loophole” you can help supercharge the gains by 10x or more!
You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history! That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords… Heck, you don’t even need a crypto wallet!
See More Headlines

CELC Stock Analysis - Frequently Asked Questions

Celcuity's stock was trading at $14.57 on January 1st, 2024. Since then, CELC stock has increased by 0.5% and is now trading at $14.64.
View the best growth stocks for 2024 here
.

Celcuity Inc. (NASDAQ:CELC) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.09.

Celcuity (CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at a price of $8.00-$10.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

Top institutional investors of Celcuity include Charles Schwab Investment Management Inc. (0.60%), Hennion & Walsh Asset Management Inc. (0.21%), BNP Paribas Financial Markets (0.12%) and Connor Clark & Lunn Investment Management Ltd. (0.06%). Insiders that own company stock include David Dalvey, Richard Nigon and Richard E Buller.
View institutional ownership trends
.

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celcuity investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/14/2024
Today
11/14/2024
Next Earnings (Confirmed)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:CELC
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.17
High Stock Price Target
$42.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+99.2%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-63,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.48 per share

Miscellaneous

Free Float
31,187,000
Market Cap
$542.12 million
Optionable
Optionable
Beta
0.76
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:CELC) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners